Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.33 |
| ▸ | NQO2 | P16083 | 2/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6413134 | 0.82 | ALDH1A1 (0.40) | ALDH1A1TAS1R3TAS1R1ACHECYP19A1 | |
| SCHEMBL14337804 | 0.78 | ALDH1A1 (0.38) | ALDH1A1TAS1R3TAS1R1ACHECYP19A1 | |
| SCHEMBL14350594 | 0.78 | ALDH1A1 (0.39) | ALDH1A1TAS1R3TAS1R1ACHECYP19A1 | |
| SCHEMBL15105430 | 0.74 | ALDH1A1 (0.42) | ALDH1A1TAS1R3TAS1R1KDM4E | |
| SCHEMBL6409992 | 0.71 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL6407920 | 0.70 | ALDH1A1 (0.33) | ALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL14337809 | 0.69 | TSHR (0.42) | ALDH1A1ACHE | |
| SCHEMBL4599330 | 0.69 | ACHE (0.40) | ALDH1A1ACHECYP19A1NQO2KDM4E | |
| SCHEMBL8400899 | 0.68 | POLB (0.43) | ALDH1A1ACHEPKM | |
| SCHEMBL10030804 | 0.68 | ACHE (0.43) | ALDH1A1ACHECYP19A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312347-B2 | Substituted optically active disphosphine compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| US-7312347-B2 | Substituted optically active disphosphine compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| US-20070073065-A1 | Substituted optically active disphosphine compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070073065-A1 | Substituted optically active disphosphine compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070073065-A1 | Substituted optically active disphosphine compound | DHPS, DOHH, DHODH | ALDH1A1 277/4885TAS1R3 4681/4885TAS1R1 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.